Paton Carol, Bassett Paul, Rendora Olivia, Barnes Thomas R E
Division of Psychiatry, Imperial College London, London, UK.
Prescribing Observatory for Mental Health, Centre for Quality Improvement, Royal College of Psychiatrists, 21 Prescot Street, London E1 8BB, UK.
Ther Adv Psychopharmacol. 2024 Oct 15;14:20451253241285883. doi: 10.1177/20451253241285883. eCollection 2024.
Optimal use of lithium involves adjustment of the dose, to keep the plasma level within the narrow, recommended range. Brand-specific prescribing has long been considered critical to achieving this aim, but this is a convention based on very limited data.
To explore the effect of selected demographic and clinical factors on the relationship between lithium dose and plasma level and determine whether there is an independent effect of lithium brand.
Analysis of clinical audit data collected in 2023 as part of a quality improvement programme addressing the use of lithium, conducted by the Prescribing Observatory for Mental Health.
Data were collected from clinical records using a bespoke proforma, submitted online and analysed using SPSS.
Data were submitted for 4405 patients who had been prescribed solid-dosage formulations of lithium for more than a year. Priadel was prescribed for 3722 (84%) of these patients, Camcolit for 112 (2.5%) and the prescription was written generically for 554 (12.5%). Compared with Priadel, where Camcolit was prescribed, the mean daily dose was 10% higher and the mean plasma lithium level was 11% higher. A multivariable analysis was conducted to explore the relationship between selected clinical variables and maintenance lithium dose. This found that in 4213 patients whose most recent plasma lithium level was between 0.3 and 1.19 mmol/L, the variables age, sex, ethnicity, psychiatric diagnosis and the severity of chronic kidney disease were independently associated with dose while the brand of lithium prescribed was not.
Our findings replicate those of previous studies with respect to the demographic and clinical variables that can be expected to influence lithium dosage in routine clinical practice. This reinforces the need to titrate the dosage for each individual patient, to achieve and maintain the target plasma level. However, the findings suggest that the Priadel and Camcolit brands of lithium are essentially interchangeable.
锂盐的最佳使用涉及调整剂量,以使血浆水平保持在狭窄的推荐范围内。长期以来,特定品牌的处方一直被认为对实现这一目标至关重要,但这是基于非常有限的数据的一种惯例。
探讨选定的人口统计学和临床因素对锂盐剂量与血浆水平之间关系的影响,并确定锂盐品牌是否有独立影响。
对2023年收集的临床审计数据进行分析,该数据是作为心理健康处方观察站开展的一项针对锂盐使用的质量改进计划的一部分。
使用定制表格从临床记录中收集数据,在线提交并使用SPSS进行分析。
提交了4405例接受锂盐固体剂型治疗超过一年患者的数据。其中3722例(84%)患者使用普利多(Priadel),112例(2.5%)使用卡姆科利特(Camcolit),554例(12.5%)为普通处方。与使用普利多的患者相比,使用卡姆科利特的患者平均日剂量高10%,平均血浆锂水平高11%。进行多变量分析以探讨选定临床变量与维持性锂盐剂量之间的关系。结果发现,在4213例最近血浆锂水平在0.3至1.19 mmol/L之间的患者中,年龄、性别、种族、精神科诊断和慢性肾病严重程度等变量与剂量独立相关,而所开锂盐品牌则无关。
我们的研究结果在可预期影响常规临床实践中锂盐剂量的人口统计学和临床变量方面重复了先前研究的结果。这强化了为每个患者滴定剂量以达到并维持目标血浆水平的必要性。然而,研究结果表明,普利多和卡姆科利特品牌的锂盐基本可互换。